Hints and tips:
Related Special Reports
...WPP’s Ogilvy advertising agency is creating a division specialising in online “health influencers” to help pharmaceutical companies tap a trend towards personalised health and combat misinformation....
Admonitions about staff trading in their employer’s shares may now need to be broadened
...The case is the latest in a series of intellectual property battles that companies are fighting around the world over mRNA technology, which has helped generate billions in revenues for the pharmaceuticals...
A company launched in 1963 confronts challenge of adapting to the rise of anti-obesity injections
...“It was one of the most epic episodes ever in pharmaceuticals history: you got an accelerated approval of a product that didn’t have a completed phase 3 trial....
US healthcare company is putting cash to work from spinning off its consumer health arm
Shah Capital wants change in US biotech’s strategy as its shares have tumbled since their pandemic peak
...Obviously, this flavour of defence is par for the course in antitrust, but we were curious whether Crevoiserat has been serving a similarly smol bean line to investors....
...Avid Bioservices, a small-cap company that helps develop and manufacture drugs for pharmaceutical companies, filed this with the SEC yesterday: On February 29, 2024, Avid Bioservices, Inc....
Advocate general of bloc’s top court says decision against world’s biggest gene sequencing group should be annulled
A weight loss titan fights to stay relevant in the age of GLP-1 drugs
...Pharmaceuticals groups Pfizer and Moderna, which have both faced criticism from fringe groups over their Covid-19 vaccines, also spent heavily on security for their CEOs last year....
...Among the surprises: the company’s investments in bitcoin and ether and the inclusion of entities affiliated with OpenAI’s Sam Altman, Silicon Valley networker par excellence, among the biggest investors...
...The Medicines and Healthcare products Regulatory Agency has approved the therapy, called Casgevy, which was developed by Vertex Pharmaceuticals and Crispr Therapeutics....
...Despite splashing out nearly $55bn on two major acquisitions over the past two years, the pharmaceutical company is worth less than it was before the pandemic....
US drugmaker is trying to chart its future without blockbuster Covid-19 products
...The company may have missed out on the early flush of AI hype but it has also avoided rushing out a sub-par product that might harm its reputation....
...O’Neill thinks tokenised bonds have moved from trial phase to implementation and are on a par with conventional bond markets, in terms of liquidity and demand....
...Both bonds were issued at a discount to par to attract investors. The bond’s guaranteed principal payment is expected to be AAA-rated by S&P, according to the World Bank....
Millions of Paxlovid pills have gone unused as tight controls restrict access
...Rival pharmaceutical groups are eager to enter the market, including AstraZeneca, which recently signed a licensing deal with Chinese company Eccogene for the rights to its weight loss pill....
...The stock is trading on 14 times forward earnings, on a par with Mattel. This seems overpriced given that Mattel has fared better sales-wise....
Doubts grow over safety and effectiveness of drugs that were marketed as coronavirus treatments
...At one point pharmaceutical company Pfizer even set out a “no jerks” policy....
Investor worries about the impact of weight loss drugs on food companies are overdone
International Edition